Pearce IP BioBlast? for the week ending 08 November 2024

Aflibercept

30 October 2024 | US | Amgen Launches Aflibercept in the US, Prepares to Launch Ustekinumab & Eculizumab

Following the Court of Appeals for the Federal Circuit’s denial of Regeneron’s application for injunction against Amgen earlier in October 2024, Amgen confirmed during its earnings… Read more here.

Bevacizumab

31 October 2024 | UK | NICE Recommends Outlook Therapeutics’ Ophthalmic Bevacizumab for Wet AMD

Outlook Therapeutics’ ophthalmic formulation of bevacizumab, Lytenava??(ONS-5010, bevacizumab gamma), has been recommended by the National Institute for Health and Care… Read more here.

Denosumab

5 November 2024 | AU | Amgen Secures Approval for 5 Additional Denosumab Brands in Australia

On 5 November 2024, the Australian Register of Therapeutic Goods (ARTG), published 5 approvals of new brands for Amgen’s denosumab, confirming Amgen’s belief that biosimilar… Read more here.

31 October 2024 | KR | Celltrion & Daewoong Pharmaceutical to Jointly Sell Denosumab Biosimilar in Korea

On 31 October 2024, Daewoong Pharmaceutical announced that it has entered a joint sales agreement with Celltrion under which the two companies will jointly promote… Read more here.

Dupilumab

6 November 2024 | EU | Dupixent? EU Approved for Children with Eosinophilic Esophagitis

On 6 November 2024, Regeneron and Sanofi announced that the EC, as recommended by CHMP, has approved Dupixent? (dupilumab) to treat eosinophilic esophagitis (EoE) in… Read more here.

Golimumab

4 November 2024 | EU | Alvotech/Advanz Announce EMA Acceptance for Biosimilar to J&J’s Simponi? (Golimumab) Confirming World First

On 4 November 2024, Alvotech and Advanz Pharma announced that the European Medicines Agency (EMA) has accepted their marketing authorisation application (MAA) for AVT05… Read more here.

Liraglutide

4 November 2024 | US | Telehealth Provider Plans to Offer Generic Liraglutide in the US From 2025

NYSE-listed telehealth provider, Hims & Hers Health Inc, announced in its third quarter 2024 earnings conference call that it plans to bring generic liraglutide to its platform… Read more here.

Trastuzumab deruxtecan

8 November 2024 | Alteogen Partners with Daiichi Sankyo on SC Enhertu? in US$300M Deal

On 8 November 2024, Korea Biomedical Review reported that Alteogen has signed an exclusive licence agreement with Daiichi Sankyo for the development and… Read more here.

Ustekinumab

4 November 2024 | EU | Celltrion’s Ustekinumab Biosimilar Launched in EU

On 4 November 2024, the Korea Hearld reported that Celltrion has launched SteQeyma?, biosimilar to Janssen’s Stelara? (ustekinumab), in Germany and the Netherlands. ?At the… Read more here.

24 September 2024 | US | Alvotech Urges FDA to Refuse to License Samsung Bioepis and Celltrion Ustekinumab Biosimilars as Interchangeable to Stelara?

On 24 September 2024, Alvotech submitted a Citizen Petition to the FDA requesting that the FDA refuse to designate any ustekinumab biosimilar as “interchangeable” with… Read more here.

Company Announcements

8 November 2024 | Celltrion’s Quarterly Sales at Record High

On 8 November 2024, Celltrion announced that it has achieved accumulated sales for Q3 2024 of KRW 2.4 trillion, surpassing its 2023 annual sales.? Its quarterly sales are the… Read more here.

6 November 2024 | Novo Nordisk Reports Strong Financial Performance

Novo Nordisk has reported strong financial performance for the first nine months of 2024.? According to a 6 November 2024 media release, company sales rose by 23%… Read more here.

6 November 2024 | Celltrion Announces Results of Preclinical Studies of Two New ADC Drug Pipelines

On 6 November 2024, Celltrion announced that it participated in the World ADC 2024 conference where it unveiled preclinical study results of two new antibody-drug conjugate… Read more here.

30 October 2024 | Biocon Biosimilar Business Grows 19% in Q3/2024 Driven by US Oncology and Insulin Franchises

On 30 October 2024, Biocon Limited announced its financial results for Q3 2024, reporting that while its total consolidated revenue was flat (year on year), it experienced… Read more here.

?

About Pearce IP

Pearce IP?is a boutique firm offering intellectual property specialist lawyers, patent attorneys and trade mark attorneys to the life sciences industries (in particular, pharmaceutical, biopharmaceutical, biotech, ag-tech and food tech).? Pearce IP is the 2021 ‘Intellectual Property Team of the Year’ (Lawyers Weekly Australian Law Awards) and was shortlisted for the same award in 2022.? Pearce IP is ranked in IAM Patent 1000 and Managing IP (MIP) IP Stars, in Australasian Lawyer 5 Star Awards as a ‘5 Star’ firm, and the?Legal 500 APAC Guide?for Intellectual Property.

Our leaders have been?recognised?in virtually every notable IP listing for their legal, patent and trade mark excellence including: IAM Patent 1000, IAM Strategy 300, MIP IP Stars, Doyles Guide, WIPR Leaders, 5 Star IP Lawyers, Best Lawyers, and Australasian Lawyer 5 Star Awards, and have been honoured with many awards including Australian Law Awards – IP Partner of the Year, Women in Law Awards – Partner of the Year, Women in Business Law Awards - Patent Lawyer of the Year (Asia Pacific), Most Influential Lawyers (Changemaker), among other awards.